Menu
Back to Journals » OncoTargets and Therapy » Volume 4
An update on TroVax® for the treatment of progressive castration-resistant prostate cancer
Authors Abern M, Kaufman H, Latchamsetty K
Published 24 May 2011 Volume 2011:4 Pages 33—41
DOI https://doi.org/10.2147/OTT.S14271
Review by Single anonymous peer review
Peer reviewer comments 5
Michael Abern1, Howard L Kaufman2, Kalyan Latchamsetty1
1Department of Urology, Rush University Medical Center, Chicago, IL, USA; 2Department of General Surgery and Immunology and Microbiology, Rush University Medical Center, Chicago, IL, USA
Abstract: Prostate cancer is a common human malignancy with few effective therapeutic options for treating advanced castration-resistant disease. The potential therapeutic effectiveness of immunotherapy and vaccines, in particular, has gained popularity based on the identification of prostate-associated antigens, potent expression vectors for vaccination, and data from recent clinical trials. A modified vaccinia Ankara (MVA) virus expressing 5T4, a tumor-associated glycoprotein, has shown promise in preclinical studies and clinical trials in patients with colorectal and renal cell carcinoma. This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax®) vaccine.
Keywords: castration resistance, prostate cancer, TroVax, vaccine
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.